ArticleDiabetologia2005
Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.
Article in Diabetologia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01847313 (Phase 3 Study of the Effect of Glucagon-like-peptide 1), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.Clinical and experimental nephrology · 2011Trial
- Identifying Key Biomarkers Related to Immune Response in the Progression of Diabetic Kidney Disease: Mendelian Randomization Combined With Comprehensive Transcriptomics and Single-Cell Sequencing Analysis.Journal of inflammation research · 2025Article
- San-Huang-Yi-Shen Capsule Ameliorates Diabetic Nephropathy in Rats Through Modulating the Gut Microbiota and Overall Metabolism.Frontiers in pharmacology · 2021Article
- Previous Exercise Training Reduces Markers of Renal Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Female Rats.Journal of diabetes research · 2018Article
- Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells.Clinical and experimental nephrology · 2017Article
- Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.Drug design, development and therapy · 2017Article
- Cytokines profile and its correlation with endothelial damage and oxidative stress in patients with type 1 diabetes mellitus and nephropathy.Immunologic research · 2016Article
- Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.Mediators of inflammation · 2014Article
- Microinflammation in the pathogenesis of diabetic nephropathy.Journal of diabetes investigation · 2013Review
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.European journal of clinical pharmacology · 2012Review
- Article
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.Diabetologia · 2011 · on this mapArticle
- Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.Clinical and experimental nephrology · 2009Review
- Pre-pubertal induction of experimental diabetes protects against early renal macrophage infiltration.Pediatric nephrology (Berlin, Germany) · 2007Article
- Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.Journal of the American Society of Nephrology : JASN · 2007Article
- Inflammation and diabetic nephropathy.Current diabetes reports · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisRecent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats.
methodsSTZ-induced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-kappaB) activity.
resultsErythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment. CONCLUSIONS/
interpretationErythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabetic rats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-kappaB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.